Real stories. Real impact. A better world.
GOOD NEWS DAILY
AllAnimalsCommunityEconomyEnvironmentHealthHumanityInnovationScienceWeekly Recap

Topic

Cancer research progress

New approvals, trial results and research in cancer care, with the stage of each result stated plainly: lab study, early trial or approved treatment.

Updated

About this topic

In 2022 there were an estimated 20 million new cancer cases and 9.7 million cancer deaths worldwide, according to the World Health Organization's cancer agency, IARC. WHO expects more than 35 million new cases a year by 2050, a 77% increase on 2022. Against that background, steady progress in diagnosis and treatment matters, even when each step is small.

The stories on this page report that progress: regulatory approvals such as the FDA's decision on pirtobrutinib for newly diagnosed chronic lymphocytic leukemia and a first-of-its-kind targeted therapy for metastatic pancreatic cancer, early trials such as high-dose vitamin B3 in glioblastoma, new tests such as a urine RNA test for bladder cancer, and laboratory research on how to keep the immune system's T cells working against tumors.

Cancer news is easy to oversell, so every story states its stage. A result in cells or mice is not a treatment, a small early trial is not proof, and an approval applies to a specific group of patients. We name the study or regulator behind each result and link to it, and we say when results come from a single company or a small number of patients.

None of these articles is medical advice. If you or someone close to you is affected, a doctor can explain whether a new treatment or trial is relevant to your situation.

Questions and answers

How many people are diagnosed with cancer each year?
There were an estimated 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022. (Source: IARC (World Health Organization))
What is the difference between phase 1, 2 and 3 cancer trials?
Phase 1 trials test whether a new treatment is safe in about 15 to 30 people, phase 2 checks whether it seems to work in 50 to 100 people, and phase 3 compares it with the current standard therapy in 100 to several thousand people. (Source: National Cancer Institute)